Telo Genomics (TSE:TELO) has released an update.
Telo Genomics Corp., a leader in telomere diagnostic and prognostic technology, has been granted prestigious accreditation by the College of American Pathologists for its laboratory quality and standards. This recognition underscores Telo Genomics’ commitment to excellence in patient care and bolsters the company’s efforts towards commercializing its innovative TeloView technology. The accreditation follows meticulous preparation and a detailed on-site inspection, ensuring the highest level of laboratory performance.
For further insights into TSE:TELO stock, check out TipRanks’ Stock Analysis page.
